FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to experimental pharmacology, and can be used to inhibit the nuclear factor kappa B (NF-kB). This method involves the addition of bacterial lipopolysaccharide at a concentration of 1 mcg/ml to the mononuclear blood cells of Wistar rats freshly isolated by the standard method of velocity sedimentation on gradient of Ficoll, which is followed by adding 5-hydroxynicotinate 3-(2,2,2-trimethylhydrazinium) potassium propionate, dissolved in phosphate-buffered saline, at a final concentration of 35 mcg/ml.
EFFECT: method allows to evaluate the inhibitory NF-kB activity of 5-hydroxynicotinate 3-(2,2,2-trimethylhydrazinium) potassium propionate.
1 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INHIBITING KAPPA NUCLEAR FACTOR WITH THE USE OF POTASSIUM 5-HYDROXYNICOTINATE IN A CELL CULTURE | 2017 |
|
RU2675693C1 |
| METHOD FOR INHIBITING NUCLEAR KAPPA B FACTOR WITH USING 2-ETHYL-6-METHYL-3-HYDROXIPIRIDINIUM L-2,6-DIAMINOHEXANOATE IN CULTURE OF CELLS | 2017 |
|
RU2669348C1 |
| USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION | 2013 |
|
RU2665362C2 |
| USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT | 2008 |
|
RU2630574C2 |
| METHOD OF CORRECTING MORPHOLOGICAL CHANGES IN PLACENTA WITH SUBSTANCE OF 3-HYDROXY-2-ETHYL-6-METHYLPYRIDINIUM NICOTINATE IN ADMA-LIKE MODEL OF PREECLAMPSIA | 2020 |
|
RU2735765C1 |
| EMPLOYMENT OF (R)-ARYLPROPIONIC ACIDS TO PREPARE DRUGS FOR TREATMENT OF HUMANS AND ANIMALS LIABLE TO BE THERAPEUTICALLY AFFECTED VIA NF-κB ACTIVATION INHIBITION | 2000 |
|
RU2250103C2 |
| 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE DERIVATIVE - 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE 5-NICOTINATE HYDROXIDE EXHIBITING ENDOTHELIOPROTECTIVE ACTIVITY | 2011 |
|
RU2467744C1 |
| 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE DERIVATIVE - 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE GLYCINATE EXHIBITING ENDOTHELIOPROTECTIVE ACTIVITY | 2011 |
|
RU2467748C1 |
| METHOD FOR CORRECTING ENDOTHELIAL DYSFUNCTION WITH SUBSTANCE OF 3-HYDROXY-2-ETHYL-6-METHYLPYRIDINIUM NICOTINATE IN AN ADMA-LIKE MODEL OF PREECLAMPSIA | 2020 |
|
RU2735903C1 |
| 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE DERIVATIVE -3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE NICOTINATE DERIVATIVE EXHIBITING ENDOTHELIOPROTECTIVE ACTIVITY | 2011 |
|
RU2465268C1 |
